GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
GO:0008630110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to DNA damage | 78/8552 | 99/18723 | 1.43e-11 | 5.08e-10 | 78 |
GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:2001235110 | Esophagus | ESCC | positive regulation of apoptotic signaling pathway | 92/8552 | 126/18723 | 3.91e-10 | 1.05e-08 | 92 |
GO:0010952111 | Esophagus | ESCC | positive regulation of peptidase activity | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CASP2 | SNV | Missense_Mutation | | c.23N>T | p.Ser8Phe | p.S8F | P42575 | protein_coding | tolerated_low_confidence(0.1) | benign(0) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CASP2 | SNV | Missense_Mutation | novel | c.905N>G | p.Asn302Ser | p.N302S | P42575 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-A2-A4RY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
CASP2 | insertion | In_Frame_Ins | novel | c.553_554insAAACACACTTCCAGCTGGTGAGTTTTTGCATAA | p.Leu190_Ala191insValSerPheCysIleLysThrHisPheGlnLeu | p.L190_A191insVSFCIKTHFQL | P42575 | protein_coding | | | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CASP2 | SNV | Missense_Mutation | | c.249N>C | p.Gln83His | p.Q83H | P42575 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CASP2 | SNV | Missense_Mutation | rs139233385 | c.794N>A | p.Arg265Gln | p.R265Q | P42575 | protein_coding | tolerated(0.28) | benign(0.011) | TCGA-VS-A9U5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CASP2 | insertion | Frame_Shift_Ins | novel | c.3_4insGCGGC | p.Pro4ArgfsTer16 | p.P4Rfs*16 | P42575 | protein_coding | | | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
CASP2 | SNV | Missense_Mutation | rs756201685 | c.907N>A | p.Ala303Thr | p.A303T | P42575 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CASP2 | SNV | Missense_Mutation | rs144817015 | c.464N>A | p.Arg155His | p.R155H | P42575 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CASP2 | SNV | Missense_Mutation | rs141615673 | c.718G>A | p.Val240Ile | p.V240I | P42575 | protein_coding | deleterious(0.05) | benign(0.029) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CASP2 | SNV | Missense_Mutation | rs370097426 | c.814N>A | p.Val272Met | p.V272M | P42575 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AZ-6599-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL197672 | EMRICASAN | |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 252166828 | | |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | | CETYLPYRIDINIUM CHLORIDE | CETYLPYRIDINIUM CHLORIDE | 18366176 |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | | SPERMINE | SPERMINE | 18366176 |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178101981 | | |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | | N-DECYLBUTYRAMIDE | CHEMBL265439 | 18366176 |